Rotenone Increases Glutamate-Induced Dopamine Release but Does Not Affect Hydroxyl-Free Radical Formation in Rat Striatum

Synapse

Volumn 50, Issue 3, 2003, Pages 240-250

  Leng, Andreas ^a   Feldon, Joram ^a   Ferger, Boris ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

In vivo microdialysis; Mitochondrial complex I; Parkinson's disease; Salicylate

Indexed keywords

DOPAMINE; GLUTAMIC ACID; HYDROXYL RADICAL; LACTIC ACID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; SALICYLIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN MITOCHONDRION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DRUG EFFECT; ENZYME INHIBITION; HYDROXYLATION; HYPOKINESIA; LEWY BODY; MALE; MICRODIALYSIS; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

AMPHETAMINE; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DENSITOMETRY; DOPAMINE; DOPAMINE AGENTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; ELECTRON TRANSPORT COMPLEX I; GLUTAMIC ACID; HYDROXYL RADICAL; HYPOKINESIA; IMMUNOHISTOCHEMISTRY; LACTIC ACID; LOCOMOTION; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICRODIALYSIS; MITOCHONDRIA; NERVE TISSUE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; ROTENONE; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE; UNCOUPLING AGENTS;

EID: 0142200794     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.10260     Document Type: Article

References (44)

1. Alam M, Schmidt WJ. 2002. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res 136: 317-324.
2. Albin RL, Greenamyre JT. 1992. Alternative excitotoxic hypotheses. Neurology 42:733-738.
3. Beal MF. 1992. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 31:119-130.
4. Beal MF. 1998. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann Neurol 44:S110-114.
5. Beal MF. 2000. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 23:298-304.
6. Beal MF. 2001. Experimental models of Parkinson's disease. Nat Rev Neurosci 2:325-334.
7. Benveniste H, Drejer J, Schousboe A, Diemer NH. 1984. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem 43:1369-1374.
8. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. 2000. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3:1301-1306.
9. Bougria M, Vitorica J, Cano J, Machado A. 1995. Implication of dopamine transporter system on 1-methyl-4-phenylpyridinium and rotenone effect in striatal synaptosomes. Eur J Pharmacol 291:407-415.
10. Budd SL, Nicholls DG. 1996. Mitochondria, calcium regulation, and acute glutamate excitotoxicity in cultured cerebellar granule cells. J Neurochem 67:2282-2291.
11. Cassarino DS, Parks JK, Parker WD Jr, Bennett JP Jr. 1999. The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Biochim Biophys Acta 1453: 49-62.
12. +. Free Radic Biol Med 13:581-583.
13. Clements JD. 1996. Transmitter timecourse in the synaptic cleft: its role in central synaptic function. Trends Neurosci 19:163-171.
14. Coyle JT, Puttfarcken P. 1993. Oxidative stress, glutamate, and neurodegenerative disorders. Science 262:689-695.
15. Ferger B, van Amsterdam C, Seyfried C, Kuschinsky K. 1998. Effects of alpha-phenyl-tert-butylnitrone and selegiline on hydroxyl free radicals in rat striatum produced by local application of glutamate. J Neurochem 70:276-280.
16. Ferrante RJ, Schulz JB, Kowall NW, Beal MF. 1997. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res 753:157-162.
17. Floyd RA, Watson JJ, Wong PK. 1984. Sensitive assay ofhydroxyl free radical formation utilizing high pressure liquid chromatography with electrochemical detection of phenol and salicylate hydroxylation products. J Biochem Biophys Methods 10:221-235.
18. Graham DG. 1978. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14:633-643.
19. Greenamyre JT, MacKenzie G, Peng TI, Stephans SE. 1999. Mitochondrial dysfunction in Parkinson's disease. Biochem Soc Symp 66:85-97.
20. Greenamyre JT, Sherer TB, Betarbet R, Panov AV. 2001. Complex I and Parkinson's disease. IUBMB Life 52:135-141.
21. Gutmann I, Wahlefeld AW. 1974. L-(+)-Lactate, determination with lactate dehydrogenase and NAD. In: Bergmeyer HU, editor. Methods in enzymatic analysis, 2nd ed. New York: Academic Press. p 1464-1468.
22. Hartley A, Stone JM, Heron C, Cooper JM, Schapira AH. 1994. Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease. J Neurochem 63:1987-1990.
23. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH. 1985. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82:2173-2177.
24. Lancelot E, Revaud ML, Boulu RG, Plotkine M, Callebert J. 1998a. A microdialysis study investigating the mechanisms of hydroxyl radical formation in rat striatum exposed to glutamate. Brain Res 809:294-296.
25. Lancelot E, Lecanu L, Revaud ML, Boulu RG, Plotkine M, Callebert J. 1998b. Glutamate induces hydroxyl radical formation in vivo via activation of nitric oxide synthase in Sprague-Dawley rats. Neurosci Lett 242:131-134.
26. Lee HJ, Shin SY, Choi C, Lee YH, Lee SJ. 2002. Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J Biol Chem 277:5411-5417.
27. Lotharius J, O'Malley KL. 2000. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J Biol Chem 275:38581-38588.
28. Lotharius J, O'Malley KL. 2001. Role of mitochondrial dysfunction and dopamine-dependent oxidative stress in amphetamine-induced toxicity. Ann Neurol 49:79-89.
29. Marey-Semper I, Gelman M, Levi-Strauss M. 1995. A selective toxicity toward cultured mesencephalic dopaminergic neurons is induced by the synergistic effects of energetic metabolism impairment and NMDA receptor activation. J Neurosci 15:5912-5918.
30. Meldrum B, Garthwaite J. 1990. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 11:379-387.
31. Mizuno Y, Ohta S, Tanaka M, Takamiya S, Suzuki K, Sato T, Oya H, Ozawa T, Kagawa Y. 1989. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 163:1450-1455.
32. Nowak L, Bregestovski P, Ascher P, Herbet A, Prochiantz A. 1984. Magnesium gates glutamate-activated channels in mouse central neurones. Nature 307:462-465.
33. Okazaki S, Nishida Y, Kawai H, Saito S. 1996. Acute neurotoxicity of L-glutamate induced by impairment of the glutamate uptake system. Neurochem Res 21:1201-1207.
34. Paxinos G, Watson C. 1998. The rat brain in stereotaxic coordinates, 4th ed. Sydney: Academic Press.
35. Peng TI, Greenamyre JT. 1998. Privileged access to mitochondria of calcium influx through N-methyl-D-aspartate receptors. Mol Pharmacol 53:974-980.
36. Ricaurte GA, Langston JW, DeLanney LE, Irwin I, Brooks JD. 1985. Dopamine uptake blockers protect against the dopamine depleting effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse striatum. Neurosci Lett 59:259-264.
37. Richmond MA, Murphy CA, Pouzet B, Schmid P, Rawlins JN, Feldon J. 1998. A computer controlled analysis of freezing behaviour. J Neurosci Methods 86:91-99.
38. Santiago M, Granero L, Machado A, Cano J. 1995. Complex I inhibitor effect on the nigral and striatal release of dopamine in the presence and absence of nomifensine. Eur J Pharmacol 280:251-256.
39. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. 1989. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1:1269.
40. Schmidt N, Ferger B. 2001. Neurochemical findings in the MPTP model of Parkinson's disease. J Neural Transm 108:1263-1282.
41. Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, Cookson MR, Greenamyre JT. 2002. An in vitro model of Parkinson's disease: Linking mitochondrial impairment to altered alphasynuclein metabolism and oxidative damage. J Neurosci 22:7006-7015.
42. Teismann P, Ferger B. 2000. Comparison of the novel drug Ensaculin with MK-801 on the reduction of hydroxyl radical production in rat striatum after local application of glutamate. Brain Res 857:165-171.
43. Themann C, Teismann P, Kuschinsky K, Ferger B. 2001. Comparison of two independent aromatic hydroxylation assays in combination with intracerebral microdialysis to determine hydroxyl free radicals. J Neurosci Methods 108:57-64.
44. Thiffault C, Langston JW, Di Monte DA. 2000. Increased striatal dopamine turnover following acute administration of rotenone to mice. Brain Res 885:283-288.